Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03177993
Other study ID # 201607068-2
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 13, 2017
Est. completion date October 24, 2019

Study information

Verified date December 2020
Source Washington University School of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Lymphatic Filariasis (LF), scabies and soil transmitted helminths (STH) are common neglected tropical diseases affecting the people of Fiji. There is a dedicated LF eradication program supported by the World Health Organization (WHO), however scabies and STH are currently managed on an individual level with symptomatic treatment as required. In an attempt to reduce the prevalence of LF globally, research is being undertaken into alternative, more effective treatment options. A recent study in Papua New Guinea demonstrated a new triple drug therapy (ivermectin, diethylcarbamazine and albendazole) is superior to the currently recommended two drug therapy (diethylcarbamazine and albendazole) used by WHO LF programs in the Pacific. However, adverse events were more frequent. Despite no serious adverse events being observed, it is necessary to conduct further studies to review the safety of this new triple therapy before it can be endorsed as an effective mass drug administration (MDA) regimen for LF in endemic countries. Fiji's burden of LF, that has been recalcitrant to previous MDA with diethylcarbamazine and albendazole, make it an ideal site to obtain further efficacy and safety data of the triple therapy. Ivermectin given to communities as MDA has been proven to be effective in reducing the community prevalence of scabies. What is not known is the effects of one dose versus two doses of ivermectin as MDA. This question will be reviewed within the design of the community randomized study. The prevalence of impetigo in a community is linked to scabies and this will also be reviewed. Ivermectin and albendazole are both effective individually against STH. The effectiveness of this combination of treatment as MDA in Fiji for STH has not been studied. The effectiveness for the individual in the short-term and the community in the longer-term will be reviewed. In addition, the acceptability and feasibility of the new therapy in communities at risk of these three diseases will be reviewed.


Recruitment information / eligibility

Status Completed
Enrollment 4773
Est. completion date October 24, 2019
Est. primary completion date November 22, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - All community members that have given written informed consent to participate Exclusion Criteria: - No informed consent

Study Design


Intervention

Drug:
3 drug dose - IDA
Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA). Participants excluded from ivermectin will receive a topical dose of permethrin cream. Exclusion criteria for ivermectin, diethylcarbamazine and albendazole: severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living); allergy to ivermectin, diethylcarbamazine or albendazole; pregnant; breastfeeding within 7 days of delivery; less than 2 years old; OR less than 15 kg In addition if less than 5 years old excluded from ivermectin. Exclusion criteria for permethrin: allergy to permethrin crusted scabies
3 drug dose - IDA with second dose of ivermectin
Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA). Eight days after treatment participants will be given a second dose of ivermectin alone. Participants excluded from ivermectin will receive a topical dose of permethrin cream both on day 0 and day 8. Exclusion criteria for ivermectin, diethylcarbamazine and albendazole: severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living); allergy to ivermectin, diethylcarbamazine or albendazole; pregnant; breastfeeding within 7 days of delivery; less than 2 years old; OR less than 15 kg In addition if less than 5 years old excluded from ivermectin. Exclusion criteria for permethrin: allergy to permethrin crusted scabies
2 drug dose - DA
Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine, and albendazole (DA). If scabies is present in the participant or a household member permethrin cream will be provided 8 days after dose of DA. Exclusion criteria for diethylcarbamazine and albendazole: severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living); allergy to diethylcarbamazine or albendazole; pregnant; breastfeeding within 7 days of delivery; less than 2 years old; OR less than 15 kg Exclusion criteria for permethrin: allergy to permethrin crusted scabies

Locations

Country Name City State
Fiji Ministry of Health and Medical Services Suva

Sponsors (3)

Lead Sponsor Collaborator
Washington University School of Medicine Murdoch Children's Research Institute, The Task Force for Global Health

Country where clinical trial is conducted

Fiji, 

Outcome

Type Measure Description Time frame Safety issue
Primary Frequency, type, and severity of adverse events reported by participants following treatment with triple drug therapy (IDA) and standard two drug therapy (DA) in LF infected and uninfected individuals in a community as measured by CTCAE v4.03 Participants will be interviewed and asked to report their general health status at baseline before receiving treatment and daily for the 2 days following treatment (Active Adverse Event Monitoring phase). For 3 to 7 days following treatment, anyone unwell the preceding day will be actively followed, other participants will be interviewed only if they feel unwell and present to the study team (Passive Adverse Event Monitoring phase).
At any stage if they describe being unwell, further questions to determine type and severity of symptom(s) experienced will be asked and recorded according to pre-defined adverse event table. If participants report moderate to severe symptoms they will have further medical assessments as required.
LF infection status will be determined by Filiarial Test Strip (FTS) and microfilariae (mf) smears.
within 7 days of drug administration
Secondary Clearance of microfilariae (mf) and filarial antigenemia following treatment with IDA or DA in LF infected individuals as measured by microfilaria count in 60ul thick blood smears and filarial test strip rapid diagnostic antigen test. Methods of assessment: FTS and Dried Blood Spot (DBS) for filarial antigenemia, mf smears for microfilariae Baseline and 12 months
Secondary Prevalence of scabies in study population measured at baseline and 12 months after treatment using the WHO Integrated Management of Childhood Illness (IMCI) skin algorithm Methods of assessment: Skin examination Baseline and 12 months
Secondary Prevalence of STH (hookworm, ascaris, trichuris and strongyloides) as measured by Kato-katz or PCR at baseline and 12 months after treatment Methods of assessment: Stool samples will be analysed using Kato-katz method, as well as PCR. Stool collected at baseline (pre-treatment), 4 weeks (individual response), and 12 months (community prevalence).
Secondary Acceptability and feasibility of IDA and DA in communities at risk of LF, scabies and STH as assessed by survey and focus group discussions. Methods of assessment: Acceptability Survey, designed specifically for the Triple therapy studies, Focus group discussions, Interviews with key informants Approximately 4 weeks following treatment
Secondary Prevalence of impetigo measured at baseline and 12 months after treatment using the WHO Integrated Management of Childhood Illness (IMCI) skin algorithm Methods of assessment: Skin examination Baseline and 12 months
See also
  Status Clinical Trial Phase
Completed NCT02572986 - A Study to Evaluate the Therapeutic Equivalence of Generic Permethrin Cream 5% to Elimite® in the Treatment of Scabies Phase 3
Completed NCT00884728 - Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia's Northern Territory N/A
Completed NCT05025696 - Efficacy and Side Effects of Blacksoap® as Adjuvant Therapy of Scabies N/A
Completed NCT04205669 - Comparing the Effectiveness of Individual vs. Household Treatment for Scabies in Lambaréné, Gabon Phase 4
Completed NCT02254564 - PCR (Polymerase Chain Reaction) Assay for Diagnosis of Sarcoptes Scabiei
Not yet recruiting NCT06404333 - Evaluating Pediatric Ivermectin in Children Under 15 kg (EPIC-15) Phase 2
Completed NCT03676140 - Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs ) Phase 3
Recruiting NCT05875441 - Efficacy and Safety Study of Moxidectin in Adults With Scabies Phase 2
Completed NCT02978508 - Bio-equivalence Study Comparing Permethrin Cream, 5% With Elimite in Patients With Active Scabies. Phase 3
Recruiting NCT04332068 - Ivermectin Safety in Small Children Phase 2
Recruiting NCT04844905 - Adjunctive Ivermectin Mass Drug Administration for Malaria Control Phase 3
Not yet recruiting NCT06380452 - Therapy for Scabies With Two Differently Concentrated Permethrin Creams Phase 3
Completed NCT00604084 - Veron Scabies Education and Eradication Program N/A
Completed NCT02485717 - Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies Phase 3
Completed NCT02485704 - Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies Phase 3
Recruiting NCT05310734 - PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age With Scabies Phase 4
Recruiting NCT04931680 - Risk Factors for Treatment Failure of Scabies in Autochthonous Populations of French Guiana (GUYAGALE)
Completed NCT06396507 - Sulfur vs. Different Regimes of Permethrin for Scabies Phase 3
Completed NCT05862701 - Comparison of Topical 5% Permethrin and Topical 10% Sulfur in the Treatment of Scabies Phase 1
Not yet recruiting NCT05500326 - Ivermectin Therapy for Scabies Infection in Children Younger Than 5 Years of Age (ITCHY Study) Phase 2